In fact, a recent study revealed that dose reduction index (DRI), which compares the dose of single drug required to achieve the same effects with the dose used in combination therapy was greatly increased when topotecan was combined with an inhibitor of RAD51 polymerization in orthotopic RB xenografts [37]. This evidence concerns the gene RAD51 and retinoblastoma.